---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-011184"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-19T23:52:55.601214+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Collegium prelim Q4/FY22 revenue at high-end of guidance; announces $175M convertible notes offering

## Summary
- Prelim FY22 product revenue $460.0M-$462.5M; Q4 $125.7M-$128.2M; both at or above prior guidance high-end.
- Prelim FY22 adjusted EBITDA $261.5M-$264.0M; Q4 adjusted EBITDA $71.9M-$74.4M.
- Announced $175M convertible senior notes due 2029, with $26.25M greenshoe option to initial purchaser.
- Intends to use part of proceeds to repurchase portion of its 2.625% 2026 convertible notes in private transactions.
- Remaining proceeds for general corporate purposes including business development, debt repayment, and shareholder returns.

## SEC filing metadata
- accession: 0001104659-23-011184
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465923011184/0001104659-23-011184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465923011184/tm235588d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-011184
- JSON: https://secwatch.observer/filing/0001104659-23-011184.json
- Plain text: https://secwatch.observer/filing/0001104659-23-011184.txt

## Key facts
- Earnings Releases
  COLLEGIUM PHARMACEUTICAL, INC reported the fiscal year ended December 31, 2022 results: revenue $460.0 million to $462.5 million.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $460.0 million to $462.5 million
  - Result: preliminary results
  source text: For the fiscal year ended December 31, 2022, we currently estimate: o Product revenues in the range of $460.0 million to $462.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465923011184/0001104659-23-011184-index.htm
- Earnings Releases
  COLLEGIUM PHARMACEUTICAL, INC reported the fourth quarter ended December 31, 2022 results: revenue $125.7 million to $128.2 million.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $125.7 million to $128.2 million
  - Result: preliminary results
  source text: For the fourth quarter ended December 31, 2022, we currently estimate: o Product revenues in the range of $125.7 million to $128.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465923011184/0001104659-23-011184-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.